2-(1-(methylsulfonyl)-1H-pyrazol-4-yl)ethyl methanesulfonate | 1280210-93-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 2-(1-(methylsulfonyl)-1H-pyrazol-4-yl)ethyl methanesulfonate
• 英文别名: 2-[1-(methylsulfonyl)-1H-pyrazoI-4-yl]ethyl methanesulfonate；2-[1-(Methylsulfonyl)-1H-pyrazol-4-yl]ethyl methanesulfonate；2-(1-methylsulfonylpyrazol-4-yl)ethyl methanesulfonate
• CAS: 1280210-93-6
• 化学式: C₇H₁₂N₂O₅S₂
• 分子量: 268.315
• InChiKey: BLMMDHKXLSPKJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  112
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(1-(methylsulfonyl)-1H-pyrazol-4-yl)ethyl methanesulfonate 、 tert-butyl {(2R,3S,5R)-2-(2,5-difiuorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]piperidin-3-yl}carbamate 在 sodium iodide sodium carbonate 作用下， 以 乙腈 为溶剂， 反应 18.0h， 生成 tert-butyl [(2R,3S,5R)-2-(2,5-difiuorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]-1-{2-[1-(methylsulfonyl)-1H-pyrazol-4-yl]ethyl}piperidin-3-yl]carbamate
  参考文献：
  名称：

  [EN] SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES
  [FR] AMINOPIPÉRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE-IV DANS LE CADRE DU TRAITEMENT DU DIABÈTE

  摘要：

  本发明涉及结构式I的新型取代氨基哌啶，它们是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。

  公开号：

  WO2011037793A1
• 作为产物：
  描述：

  2-(1H-吡唑-4-基)乙醇 、 甲基磺酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以62%的产率得到2-(1-(methylsulfonyl)-1H-pyrazol-4-yl)ethyl methanesulfonate
  参考文献：
  名称：

  [EN] LYSYL OXIDASE INHIBITORS
  [FR] INHIBITEURS DE LA LYSYLE OXYDASE

  摘要：

  这项发明涉及作为赖氨酸氧化酶（LOX）和赖氨酸氧化酶类（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）抑制剂有用的化合物。此外，还考虑了包括这些化合物的药物组合物以及利用这些化合物治疗由LOX和LOXL介导的疾病，例如癌症。特别是像目前的这些化合物这样的LOX抑制剂可能用于治疗与EGFR相关的癌症。本发明还考虑了预测对LOX抑制剂响应性的生物标志物的鉴定。

  公开号：

  WO2019073251A1

文献信息

• SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES
  申请人：Cox Jason M.

  公开号：US20120149683A1

  公开（公告）日：2012-06-14

  The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ÏV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基哌啶化合物，它们是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病和特别是2型糖尿病方面具有用途。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶参与的这些疾病方面使用这些化合物和组合物。
• Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
  申请人：Cox Jason M.

  公开号：US08716482B2

  公开（公告）日：2014-05-06

  The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ÏV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新型的取代氨基哌啶化合物，其化学结构式为I，是二肽基肽酶IV酶的抑制剂，可用于治疗或预防二肽基肽酶ÏV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗二肽基肽酶IV酶参与的疾病方面的应用。
• Lysyl oxidase inhibitors
  申请人：The Institute of Cancer Research: Royal Cancer Hospital

  公开号：US11325915B2

  公开（公告）日：2022-05-10

  This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.

  本发明涉及可用作赖氨酰氧化酶（LOX）和赖氨酰氧化酶样（LOXL）家族成员（LOXL1、LOXL2、LOXL3、LOXL4）抑制剂的化合物。此外，还考虑了包含这些化合物的药物组合物以及这些化合物在治疗由 LOX 和 LOXL 介导的疾病（例如癌症）中的用途。特别是LOX抑制剂，如本发明化合物，可用于治疗与表皮生长因子受体相关的癌症。本发明还考虑鉴定预测对 LOX 抑制剂反应性的生物标志物。
• LYSYL OXIDASE INHIBITORS
  申请人：The Institute of Cancer Research: Royal Cancer Hospital

  公开号：US20200331922A1

  公开（公告）日：2020-10-22

  This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
• US8716482B2
  申请人：——

  公开号：US8716482B2

  公开（公告）日：2014-05-06